BRPI0415232A - uso de xenÈnio com hipotermia para tratar asfixia neonatal - Google Patents

uso de xenÈnio com hipotermia para tratar asfixia neonatal

Info

Publication number
BRPI0415232A
BRPI0415232A BRPI0415232-8A BRPI0415232A BRPI0415232A BR PI0415232 A BRPI0415232 A BR PI0415232A BR PI0415232 A BRPI0415232 A BR PI0415232A BR PI0415232 A BRPI0415232 A BR PI0415232A
Authority
BR
Brazil
Prior art keywords
xenon
hypothermic
neonatal asphyxia
treat neonatal
asphyxia
Prior art date
Application number
BRPI0415232-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Nicholas Peter Franks
Mervyn Maze
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34436835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0415232(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0323861A external-priority patent/GB0323861D0/en
Priority claimed from GB0418539A external-priority patent/GB0418539D0/en
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Publication of BRPI0415232A publication Critical patent/BRPI0415232A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0415232-8A 2003-10-10 2004-10-11 uso de xenÈnio com hipotermia para tratar asfixia neonatal BRPI0415232A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0323861A GB0323861D0 (en) 2003-10-10 2003-10-10 Use
GB0418539A GB0418539D0 (en) 2004-08-19 2004-08-19 Use
PCT/GB2004/004298 WO2005034966A1 (en) 2003-10-10 2004-10-11 Use of xenon with hypothermia for treating neonatal asphyxia

Publications (1)

Publication Number Publication Date
BRPI0415232A true BRPI0415232A (pt) 2006-12-12

Family

ID=34436835

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415232-8A BRPI0415232A (pt) 2003-10-10 2004-10-11 uso de xenÈnio com hipotermia para tratar asfixia neonatal

Country Status (13)

Country Link
US (1) US7390508B2 (cg-RX-API-DMAC7.html)
EP (1) EP1670489B1 (cg-RX-API-DMAC7.html)
JP (1) JP4880466B2 (cg-RX-API-DMAC7.html)
AT (1) ATE380554T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004280118B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415232A (cg-RX-API-DMAC7.html)
CA (1) CA2538104C (cg-RX-API-DMAC7.html)
DE (1) DE602004010691T2 (cg-RX-API-DMAC7.html)
DK (1) DK1670489T3 (cg-RX-API-DMAC7.html)
ES (1) ES2298815T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA06003471A (cg-RX-API-DMAC7.html)
PT (1) PT1670489E (cg-RX-API-DMAC7.html)
WO (1) WO2005034966A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2538104C (en) * 2003-10-10 2013-12-10 Protexeon Limited Use of xenon with hypothermia for treating neonatal asphyxia
GB0418540D0 (en) 2004-08-19 2004-09-22 Protexeon Ltd Use
GB0520176D0 (en) * 2005-10-04 2005-11-09 Imp College Innovations Ltd Use
ITMI20071031A1 (it) * 2007-05-22 2008-11-23 Acetilene & Deriv Ati Siad Spa Uso di xenon per la protezione di organi da danno ischemico
AU2014277860A1 (en) * 2008-01-22 2015-01-22 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
WO2009094460A2 (en) * 2008-01-22 2009-07-30 Vapogenix, Inc. Volatile anesthetic compositions and methods of use
EP2427243A4 (en) * 2009-05-05 2012-11-21 Vapogenix Inc NEW FORMULATIONS OF VOLATILE ANESTHETICS AND METHOD OF ADMINISTRATION
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
WO2014145443A2 (en) 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
FR3021220B1 (fr) * 2014-05-21 2017-08-25 Air Liquide Association de xenon et d’un antioxydant pour lutter contre une maladie neurodegenerative de type maladie de parkinson
EP3313384A4 (en) * 2015-06-23 2019-04-03 Nobilis Therapeutics, Inc. THERAPEUTIC IMMUNE MODULATION USING NOBLE GAS COMPOSITIONS
US10022397B2 (en) * 2016-06-20 2018-07-17 Nobilis Therapeutics, Inc. Treatment of rheumatoid arthritis using noble gas mixtures

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099834A (en) * 1991-07-16 1992-03-31 Union Carbide Industrial Gases Technology Corporation Method for anesthesia
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
DE19910986C2 (de) * 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
DE19933704A1 (de) * 1999-07-19 2001-01-25 Michael Georgieff Verwendung einer lipophile Gase enthaltenden Präparation zur Neuroprotektion und Neuroregeneration
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
US6653354B2 (en) 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
WO2001078580A2 (en) * 2000-03-31 2001-10-25 Innercool Therapies, Inc. A method combining inducing hypothermia and administering a therapeutic agent
CA2538104C (en) * 2003-10-10 2013-12-10 Protexeon Limited Use of xenon with hypothermia for treating neonatal asphyxia

Also Published As

Publication number Publication date
CA2538104C (en) 2013-12-10
DE602004010691T2 (de) 2008-12-04
AU2004280118B2 (en) 2009-01-15
EP1670489B1 (en) 2007-12-12
ES2298815T3 (es) 2008-05-16
JP4880466B2 (ja) 2012-02-22
MXPA06003471A (es) 2006-06-14
EP1670489A1 (en) 2006-06-21
US20070104796A1 (en) 2007-05-10
PT1670489E (pt) 2008-02-28
ATE380554T1 (de) 2007-12-15
DE602004010691D1 (de) 2008-01-24
WO2005034966A1 (en) 2005-04-21
JP2007508284A (ja) 2007-04-05
US7390508B2 (en) 2008-06-24
DK1670489T3 (da) 2008-01-07
AU2004280118A1 (en) 2005-04-21
CA2538104A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
IL192103A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
PH12011502704A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
CL2007002382A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel.
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
EA200601777A1 (ru) Новое применение пептидных соединений для лечения боли при болезненной диабетической нейропатии
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
DK1670489T3 (da) Brug af xenon med hypotermi til behandling af neonatal asfyksi
EA201070195A1 (ru) ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРРОЛО [1,2-А]ПИРАЗИН-6-КАРБОКСАМИДОВ И 2,3,4,5-ТЕТРАГИДРОПИРРОЛО [1,2-a][1,4]-ДИАЗЕПИН-7-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
PT1220676E (pt) Prevencao do cancro colorrectal
CY1108501T1 (el) Συνθεση δια την προληψη και θεραπευτικη αγωγη ασθενειων κρυολογηματος
HRP20090513T1 (hr) S-mirtazapin, namijenjen liječenju napadaja vrućine
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
EA200801890A1 (ru) Средство для лечения шума в ушах
BRPI0410998A (pt) derivados de indol com efeito de indução de apoptose
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
PA8624501A1 (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis
PL1818052T3 (pl) Zastosowanie formoterolu w profilaktycznym i/lub terapeutycznym leczeniu wyniszczenia mięśniowego i/lub zespołu wyniszczenia, związanych ze stanami katabolicznymi w przebiegu niektórych chorób, takich jak nowotwory, AIDS, zakażenia, cukrzyca i inne
TW200605891A (en) Use of 7-t-butoxyiminomethylcamptothecin for the preparation of a medicament for the treatment of uterine neoplasms
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: PROTEXEON LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: IMPERIAL INNOVATIONS LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL